Unknown

Dataset Information

0

"Para-retinal" Vector Administration into the Deep Vitreous Enhances Retinal Transgene Expression.


ABSTRACT: Intravitreal administration for human adeno-associated vector (AAV) delivery is easier and less traumatic to ocular tissues than subretinal injection, but it gives limited retinal transduction. AAV vectors are large (about 4,000 kDa) compared with most intraocular drugs, such as ranibizumab (48 kDa), and the large size impedes diffusion to reach the retina from the usual injection site in the anterior/mid-vitreous. Intuitively, a preferred placement for the vector would be deep in the vitreous near the retina, which we term "para-retinal" delivery. We explored the consequences of para-retinal intravitreal delivery in the rabbit eye and in non-human primate (NHP) eye. 1 h after para-retinal administration in the rabbit eye, the vector concentration near the retina remained four times greater than in the anterior vitreous, indicating limited vector diffusion through the gelatinous vitreous matrix. In NHP, para-retinal placement showed greater transduction in the fovea than vector applied in the mid-vitreous. More efficient retinal delivery translates to using lower vector doses, with reduced risk of ocular inflammatory exposure. These results indicate that para-retinal delivery yields more effective vector concentration near the retina, thereby increasing the potential for better retinal transduction in human clinical application.

SUBMITTER: Zeng Y 

PROVIDER: S-EPMC7363691 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

"Para-retinal" Vector Administration into the Deep Vitreous Enhances Retinal Transgene Expression.

Zeng Yong Y   Boyd Ryan R   Bartoe Joshua J   Wiley Henry E HE   Marangoni Dario D   Wei Lisa L LL   Sieving Paul A PA  

Molecular therapy. Methods & clinical development 20200624


Intravitreal administration for human adeno-associated vector (AAV) delivery is easier and less traumatic to ocular tissues than subretinal injection, but it gives limited retinal transduction. AAV vectors are large (about 4,000 kDa) compared with most intraocular drugs, such as ranibizumab (48 kDa), and the large size impedes diffusion to reach the retina from the usual injection site in the anterior/mid-vitreous. Intuitively, a preferred placement for the vector would be deep in the vitreous n  ...[more]

Similar Datasets

| S-EPMC6350231 | biostudies-literature
| S-EPMC10284706 | biostudies-literature
| S-EPMC7416894 | biostudies-literature
| S-EPMC3666624 | biostudies-literature
| S-EPMC5493822 | biostudies-literature
| S-EPMC3463356 | biostudies-literature
| S-EPMC11705503 | biostudies-literature
| S-EPMC5507306 | biostudies-literature
| S-EPMC5264529 | biostudies-literature
| S-EPMC6881693 | biostudies-literature